2018
Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients
Blood 

Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia
PLOS One

A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma
​Clinical Cancer Research | AACR

Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma
​Nature | Leukemia

Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche
​Nature | Leukemia

Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation
​Blood Advances | American Society of Hematology
​
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma
British Journal of Hematology

Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma
​Nature Communications

Current use of monoclonal antibodies in the treatment of multiple myeloma
British Journal of Hematology

Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab
​Molecular Cancer Therapeutics | AACR

Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression
Journal of Clinical Investigation

Targeting MYC in multiple myeloma
Leukemia | Nature

Platelets Enhance Multiple Myeloma Progression via IL-1β Upregulation
Clinical Cancer Research| AACR

The bone-marrow niche in MDS and MGUS: implications for AML and MM
Nature Reviews | Clinical Oncology